Outcomes of primary refractory multiple myeloma and the impact of novel therapies

Over the past decade, use of novel agents, including immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs) has resulted in high response rates and improvement in overall survival (OS) for patients with multiple myeloma (MM); however, the prognostic significance of refractoriness to these ag...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Am J Hematol
Auteurs principaux: Majithia, Neil, Rajkumar, S. Vincent, Lacy, Martha Q., Buadi, Francis K., Dispenzieri, Angela, Gertz, Morie A., Hayman, Suzanne R., Dingli, David, Kapoor, Prashant, Hwa, Lisa, Lust, John A., Russell, Stephen J., Go, Ronald S., Kyle, Robert A., Kumar, Shaji K.
Format: Artigo
Langue:Inglês
Publié: 2015
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5801545/
https://ncbi.nlm.nih.gov/pubmed/26214732
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.24131
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires